Connect with us

Hi, what are you looking for?


Jim Cramer: buy Abbott stock after its Q1 earnings report

Abbott Laboratories (NYSE: ABT) is up 8.0% this morning after reporting strong results for its fiscal Q1 despite a significant slowdown in sales of COVID-19 tests.

Jim Cramer’s view on Abbott stock

The health care company continues to see $4.30 a share to $4.50 a share of earnings this year on at least a high single-digit percentage growth in organic sales.

That was sufficient for famed investor and Mad Money host Jim Cramer to recommend buying Abbott stock today.

Abbott is a clear winner. They’ve got some franchises that are amazing. Diabetes franchise is very strong. They’re telling a very good story. They are now past COVID. Clear beat, well done.

Nutrition and medical devices did great in Q1

Abbott Laboratories took a 47% hit to its diagnostics revenue in the recent quarter as COVID tests sales crashed from $3.3 billion a year ago to $730 million.

It was, however, offset by the strength in the company’s nutrition and medical devices business. On CNBC’s “Squawk on the Street”, Cramer added:

They have the scale, they have Libre, a way to measure glucose. It’s a fabulous inexpensive device that could be a $10 billion franchise without a problem and the Street is not recognising it.

Abbott stock is currently just under its year-to-date high.

Abbott Laboratories Q1 earnings snapshot

Earned $1.32 billion versus the year-ago $2.45 billion

Per-share earnings also tanked from $1.37 to 75 cents

Adjusted EPS printed at $1.03 as per the press release

Sales declined 18% year-over-year to $9.75 billion

Consensus was 99 cents EPS on $9.67 billion revenue

The multinational agreed, though, that sales of its COVID tests will bring in $1.5 billion in 2023 versus $2.0 billion it had guided for earlier. Still, Cramer said:

The presentation was extraordinarily clean and good, it made you feel very confident in buying this one.

The post Jim Cramer: buy Abbott stock after its Q1 earnings report appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Latest News

    Rep. Jennifer Wexton (D-Va.) announced on Tuesday that she has been diagnosed with Parkinson’s Disease. “If there’s one thing that Democrats and Republicans can...

    Latest News

    After Dianne Feinstein announced she’d contracted the shingles in early March, her staff said she planned to return to the Senate within a matter...


    A U.S. District Court judge has ruled that Elizabeth Holmes, founder and CEO of the disgraced blood-testing company Theranos, cannot remain free on bail...

    Latest News

    SEOUL, South Korea — When a group of American lawmakers arrived in South Korea for meetings with government and military officials, President Yoon Suk-yeol...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2022 All Rights Reserved.